Biomedical Journal · 2019 · 69 citations · 60 references
MedicineOncologyPharmacologyApoptosisCancer PharmacologyMolecular OncologyApoptosis PharmacologyApoptosis ResistanceBreast Cancer PharmacotherapyPharmacodynamics Of Anticancer AgentsPharmacodynamics Of Anticancer DrugsApoptotic Signaling DysregulationBreast Cancer ProgressionCell-based AssaysCell-based Pharmacological AssaysPro-apoptotic ProteinsPropranolol TherapyTumor Cell ProliferationTumor Proliferation Assessment
BACKGROUND: Substantial evidence supports the use of inexpensive β-AR antagonists (beta blockers) against a variety of cancers, and the β-AR antagonist propranolol was recently approved by the European Medicines Agency for the treatment of soft tissue sarcomas. Prospective and retrospective data published by our group and others suggest that non-selective β-AR antagonists are effective at reducing proliferative rates in breast cancers, however the mechanism by which this occurs is largely unknown. METHODS: In this study, we measured changes in tumor proliferation and apoptosis in a late stage breast cancer patient treated with neoadjuvant propranolol. We expounded upon these clinical findings by employing an in vitro breast cancer model, where we used cell-based assays to evaluate propranolol-mediated molecular alterations related to cell proliferation and apoptosis. RESULTS: Neoadjuvant propranolol decreased expression of the pro-proliferative Ki-67 and pro-survival Bcl-2 markers, and increased pro-apoptotic p53 expression in a patient with stage III breast cancer. Molecular analysis revealed that β-AR antagonism disrupted cell cycle progression and steady state levels of cyclins. Furthermore, propranolol treatment of breast cancer cells increased p53 levels, enhanced caspase cleavage, and induced apoptosis. CONCLUSION: Collectively, these data provide support for the incorporation of β-AR antagonists into the clinical management of breast cancer, and elucidate a partial molecular mechanism explaining the efficacy of β-AR antagonists against this disease.
60
The Sympathetic Nervous System Induces a Metastatic Switch in Primary Breast Cancer
Erica K. Sloan, Saul J. Priceman, Benjamin F. Cox et al. · Cancer Research · 2010 · 893 citations · Full text
Medicine, Oncology, Pharmacology +17
Beta Blockers and Breast Cancer Mortality: A Population- Based Study
Thomas I. Barron, Roisín M. Connolly, Linda Sharp et al. · Journal of Clinical Oncology · 2011 · 518 citations
Medicine, Oncology, Pharmacology +14